Dr. Brian W Tempest www.briantempest.com
Pharmaceuticals & Global Health
Sussex University Conference Centre , Brighton, UK
19 July 2013
Hale & Tempest

Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade.
Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until
2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip
MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional
Director Far East and Regional Director Middle East & Africa from 1985 to 1992.
Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world.
He is now Independent Chairman of Religare Capital Markets PLC , a Non Executive Director of
Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of
Generic Medicines. Brian speaks at global conferences and more information on these presentations can be found on his website www.briantempest.com.
Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became
Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a
Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a
Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd
Hale & Tempest

Healthcare costs versus GDP & Wages
Hale & Tempest

Everybody Concerned about Health Costs
Hale & Tempest

Increasing Generics & Biosimilars
Hale & Tempest

A Slide from a UK Headhunter
Hale & Tempest

Pharma in Crisis
Source: Pharmatimes February 2013
Hale & Tempest

Generics versus Big Pharma
Hale & Tempest

Patent Cliff to 2018 source: Evaluate Pharma, Sandoz
Hale & Tempest

Top 25 Global Generic Companies
Source: Generics Bulletin 10 June 2011
Hale & Tempest

Products Going Off Patent in 2015 $33b
Source: Evaluate Pharma 14 February 2013
Hale & Tempest

The Teva Future – Standing Still
Source: RBC Capital 12 December 2012
Hale & Tempest

Global footprint of Watson/Actavis – excluding most of the developing world
Hale & Tempest

Indian Generic Cos continue to grow
Source: Pharmatimes World News Feb 5 2013
• Many Indian Companies in 2013 showing a sales growth of >20%
• Indian Pharma Exports 2008-2012 around the World have shown a %CGR of +19% in sales
• New Product Pipeline in USA ANDAs shows approvals from India in 2012 was 37% with 178 out of a total of 476 and in 2011 33% with 144 out of 431
• New ANDA filings of ANDAs in the USA from India indicate 51% in 2011 and 49% in 2010
Hale & Tempest

India’s First Compulsory Licence after 3 years at a high price
Source : Economic Times 13 March 2012
Hale & Tempest

More CLs on the way in India
Source: 29 March 2013
Hale & Tempest

India Patent dismissed for Evergreening
Source: Financial Express 2 April 2013
Hale & Tempest

Anti Cancer Drugs At Delhi Airport
Source: New Delhi Airport 28 March 2013
Hale & Tempest

But Indian Price Cuts source: Hindustan Times 20 June 2013
Hale & Tempest

Aggressive EU-India Bilateral FTA
Source: ET 27 March 2013
Hale & Tempest

The Future of IP?
• In 2012 Big pharma had the best NCE year since 1997
• There are $230b sales going off patent in 2013-2018 but only half will be replaced by generics owing to biologics
• Big Pharma is finding the BRICS markets tough
• More CLs likely from the BRICS countries owing to evergreening or a very high price limiting access
• Do all patents need to be 20 years? The first USA patent law in 1790 was for 14 years.
Hale & Tempest
• What is the point of a patent if only the rich can use it?

brian.tempest@clara.co.uk
www.briantempest.com
Hale & Tempest